达丁类药物的使用和患有糖尿病的人群中帕金森病的风险:一项嵌套病例对照研究
Kim Honkamaa1, Anne Paakinaho1,2, Anna-Maija Tolppanen1,2
1School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
British journal of clinical pharmacology
|March 13, 2024
概括
这项研究发现,糖尿病患者使用他类药物并没有降低帕金森病 (PD) 的风险. 较高的累积他类药物暴露与PD风险增加有关.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病患者面临患帕金森病 (PD) 的风险增加.
- 常见的处方是静止剂药物,它们可能会影响神经退行性过程.
研究的目的:
- 在患有糖尿病的人群中调查他类药物使用与帕金森病 (PD) 风险之间的联系.
- 为了确定他类药物暴露是否会改变糖尿病患者的PD风险.
主要方法:
- 一项全国性的嵌套病例控制研究是使用芬兰健康登记册进行的.
- 包括2017个PD病例和7934个与糖尿病匹配的对照,分析了1995-2015年的他类药物使用情况.
- 条件后勤回归调整为并发症和抗糖尿病药物使用,具有3年的暴露延迟时间.
主要成果:
- 在帕金森病 (PD) 病例 (54.2%) 和对照病例 (54.4%) 之间,他类药物的使用率相似.
- 与非使用者 (aOR=1.22) 和最低的三分之一 (aOR=1.29) 相比,最高累积他类药物暴露的三分之一显示了更高的PD风险.
结论:
- 这项研究不支持使用他类药物减少糖尿病患者帕金森病 (PD) 风险的假设.
- 调查结果表明,在这个人群中,随着较高的累计他类药物暴露,PD的风险可能会增加.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Psychoneuroimmunology: Diabetes and Cancer
29
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
29


